Relapse is the major cause of treatment failure after allogeneic transplantation of children with juvenile myelomonocytic leukemia (JMML), and the role of post-transplant immunomodulation is poorly understood. We report a 12-month-old child with JMML relapsed after unrelated marrow transplantation who received cytoreduction followed by donor lymphocyte infusion (DLI) with improvement, and after addition of interferon-alpha (IFN) achieved complete donor chimerism. He was weaned from IFN and has maintained complete remission for 19 months. This is the first published report of a patient with non-monosomy-7 JMML responding to post-transplant immunomodulation and suggests a role for DLI plus IFN in these patients. Juvenile myelomonocytic leukemia (JMML) is a rare pediatric malignancy, which presents in infancy or early childhood with myeloproliferative features and hepatosplenomegally. Monosomy-7 occurs in one-quarter of these patients, and although JMML with monosomy-7 may progress more slowly, long-term outcome is the same as non-monosomy-7 JMML (10-year overall survival 6%).
allogeneic stem cell transplantation; donor lymphocyte infusion (DLI); interferon-alpha; graft-versus-leukemia (GVL) Juvenile myelomonocytic leukemia (JMML) is a rare pediatric malignancy, which presents in infancy or early childhood with myeloproliferative features and hepatosplenomegally. Monosomy-7 occurs in one-quarter of these patients, and although JMML with monosomy-7 may progress more slowly, long-term outcome is the same as non-monosomy-7 JMML (10-year overall survival 6%). 1 Hematopoietic cell transplantation has led to improved outcome, with reports of 2-to 4-year overall survival varying from 24% (NMDP) to 54% (Japanese data). 2, 3 The major cause of failure is relapse, with rates as high as 58% at 2 years. 2 In spite of the well-documented efficacy of post transplant immunomodulation in other disorders, published work suggesting a graft-versus-leukemia (GVL) effect of post-transplant donor lymphocyte infusion (DLI) or intereferon in JMML is limited, and responding patients have all had monosomy-7 JMML. [4] [5] [6] We describe a patient who relapsed early after unrelated allogeneic bone marrow transplantation for non-monosomy-7 JMML in whom DLI induced a partial response, and the addition of interferon-alpha (IFN) likely contributed to attaining and sustaining a prolonged complete remission. This observation suggests a role for post-transplant immunotherapy approaches in non-monosomy-7 JMML.
Clinical history
The patient presented at age 6 months with hepatosplenomegally, thrombocytopenia, and GI bleeding. Initial WBC was 42.8 Â 10 9 /l and marrow assessment showed JMML (based on the International JMML Working Group criteria).
1 Cytogenetics were normal. The patient underwent a splenectomy followed by two courses of cytoreductive chemotherapy with flu/ara-C (fludarabine 30 mg/m 2 /day Â 5 days and cytosine arabinoside 2 g/m 2 / day Â 5 days), resulting in pathologic complete remission.
The patient then underwent allogeneic stem cell transplant utilizing a preparative regimen of TBI (total 1200 cGy), cyclophosphamide (60 mg/kg Â 2), and ATG (total 75 mg/kg). Bone marrow from a 6/6 matched unrelated donor was infused with a dose of 12 Â 10 6 CD34 þ cells/kg. GVHD prophylaxis consisted of cyclosporin and short-course methotrexate. Stage 3 skin (overall grade II, Glucksberg) acute GVHD was noted just after engraftment, but resolved with topical therapy. Day þ 100 whole blood chimerism by VNTR analysis was 90% donor, prompting initiation of a cyclosporin taper over 4 weeks. In spite of recurrent skin GVHD during the taper, whole blood chimerism worsened to 13% donor. Once the GVHD was stabilized, immune suppression was tapered completely over 8 weeks.
Because of progressive relapse (increasing WBC, worsening donor chimerism (10%), and bone marrow morphology confirming relapsed JMML), another course of flu/ara-C was given followed by DLI at a dose of 1 Â 10 6 CD3 þ cells/kg. At 6 weeks after DLI #1, whole blood donor chimerism was unchanged, T-cell chimerism fell to 65%, and morphologic progressive disease was noted. At that point, another round of flu/ara-C chemotherapy followed by a second DLI at a dose of 1 Â 10 7 CD3 þ cells/kg was given (see Figure 1) . At 5 weeks after the second DLI dose, whole blood and T-cell donor chimerism increased to 70 and 499%, respectively. With residual leukemia a third DLI was considered, but the patient's family declined due to increased risk of severe GVHD associated with further DLI escalation. At that point (6 weeks after DLI #2), IFN therapy was started at a dose of 1.4 million units subcutaneously 2 Â /week. The dose was escalated over the next 8 weeks to 2 million units every other day. At 2 weeks after starting IFN, whole blood chimerism increased to just above 90% where it remained for 2 months. Just after reaching the highest dose of interferon, whole blood and T-cell donor chimerism became 100%. This dose was maintained for 6 months, followed by a decrease to twice weekly for 3 months, then weekly for 3 months. IFN toxicities included fever and grade III thrombocytopenia and anemia. Currently, the patient has been off IFN for 8 months and has normal counts, no GVHD, and 100% donor whole blood chimerism.
Discussion
While the literature has hinted at a GVL effect in JMML, 2 only two papers have reported positive outcomes with DLI. 4, 5 Mathes-Martin et al described two JMML patients relapsed after BMT treated with DLI: one patient failed to respond to a dose of 1 Â 10 7 CD 3 þ cells/kg and a second patient with monosomy-7 JMML remained in remission 9 months after receiving chemotherapy followed by three DLI doses (0.5 Â 10 6 Â 2, 1.0 Â 10 6 Â 1 CD3 þ cells/kg). Worth et al described another patient with monosomy-7 JMML relapsed after BMT who received DLI at a dose of 1 Â 10 8 CD3 þ cells/kg. The patient developed significant GVHD requiring steroid therapy which resolved and was reported as disease free 17 months after DLI.
IFN has been used by several groups to treat relapse after allogeneic transplant with or without DLI. [7] [8] [9] The efficacy of IFN post transplant is improved when tumor burden is less (in CML durable complete responses occurred in 45-57% of patients with cytogenetic relapse vs 28% of patients with hematologic relapse). 8, 9 With our patient we achieved tumor debulking with chemotherapy followed by DLI, but one other reported JMML case may have benefited from rapid withdrawal of immune suppression followed by IFN. This post-transplant patient with monosomy-7 JMML started IFN 1 week after stopping tacrolimus abruptly at the time of relapse. The patient achieved 100% donor chimerism 2 months after starting IFN, maintaining the CR for 7 months on IFN and bestatin therapy at the time of the report. 6 Mackinnon et al demonstrated that escalating DLI doses could achieve complete leukemia response with less GVHD. 10 Following this approach, we gave cytoreductive chemotherapy followed by an initial DLI dose of 1 Â 10 6 CD3 þ cells/kg resulting in progressive disease and worsening donor T-cell chimerism. Using the same cytoreductive therapy and a higher a dose of DLI (1 Â 10 7 CD3 þ cells/kg), we noted a partial response (increase of donor T cells from 65 to 99% and increase of whole blood donor chimerism from 10 to 70%) suggesting that the increased dose of DLI rather than the chemotherapy led to the response. To treat the remaining leukemic burden we added IFN, hoping to avoid the well-documented increased risk of severe GVHD when escalating DLI further.
10 IFN was started 6 weeks after the second DLI, and 2 weeks later whole blood chimerism increased from 70 to 90%. It took another 8-10 weeks, however, with escalating doses of IFN to achieve 100% donor chimerism. While this effect could possibly be explained by a late remission from DLI #2 alone, the slow course leading to full donor chimerism as well as the sustained response in the absence of clinical GVHD suggests that IFN had an immunomodulatory effect, resulting in sustained full donor chimerism. This patient is an interesting illustration of the two major effects of IFNantiproliferation (grade III thrombocytopenia and anemia) and immunomodulation (increased donor chimerism). Whether this patient needed DLI or could have responded to IFN alone is unknown, but as mentioned above, the immunomodulatory effect of IFN improves when tumor burden is minimized. 8, 9 It has been suggested by some authors that DLI is only effective in patients with monosomy-7-associated JMML; 4, 5 however, this was not the case with our patient, suggesting that immunomodulation may be considered in patients with all types of JMML. This experience further suggests that a sequential approach to post-transplant immunotherapy using cytoreduction followed by low-dose DLI to decrease tumor burden and possibly IFN for consolidation may have the potential to decrease toxicity associated with high-dose DLI while preserving a clinically meaningful graft-versus-JMML effect. 
